NCT05415943View on ClinicalTrials.gov

Safety and Efficacy Assessment of Diagnostic Microprobe (inPROBE) in Women at High Risk of Breast Cancer (Part I Study)

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

March 2, 2023

Study Completion Date

March 2, 2023

Conditions
Breast Cancer
Interventions
DEVICE

Diagnostic microprobe (inPROBE) medical device

Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.

Trial Locations (2)

30-688

Uniwersyteckie Centrum Leczenia Chorób Piersi, Szpital Uniwersytecki w Krakowie, Krakow

20-081

Klinika Chirurgii Onkologicznej, Lublin

All Listed Sponsors
lead

SDS Optic S.A.

INDUSTRY